Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Heron Therapeutics (HRTX)

Heron Therapeutics (HRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Heron Therapeutics 100 REGENCY FOREST DRIVE SUITE 300 CARY NC 27518 USA

www.herontx.com Employees: 122 P: 858-251-4400

Sector:

Medical

Description:

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.

Key Statistics

Overview:

Market Capitalization, $K 243,873
Enterprise Value, $K 243,103
Shares Outstanding, K 183,363
Annual Sales, $ 144,290 K
Annual Net Income, $ -13,580 K
Last Quarter Sales, $ 38,210 K
Last Quarter Net Income, $ -17,500 K
EBIT, $ 1,590 K
EBITDA, $ 2,900 K
60-Month Beta 1.34
% of Insider Shareholders 5.86%
% of Institutional Shareholders 80.01%
Float, K 172,618
% Float 94.14%
Short Volume Ratio 0.32

Growth:

1-Year Return -22.16%
3-Year Return -50.00%
5-Year Return -92.69%
5-Year Revenue Growth -1.15%
5-Year Earnings Growth 96.40%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.05 on 11/04/25
Next Earnings Date 02/26/26
Earnings Per Share ttm -0.04
EPS Growth vs. Prev Qtr -150.00%
EPS Growth vs. Prev Year -66.67%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 01/13/14

HRTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -1.95%
Profit Margin % -9.41%
Debt/Equity 7.22
Price/Sales 1.72
Price/Cash Flow N/A
Price/Book 35.25
Book Value/Share 0.08
Interest Coverage -1.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar